###### Strengths and limitations of this study

-   The strengths of our study are its population-based design, and generalisability of findings with a very large sample size including study and control cohorts.

-   All insurance claims should be scrutinised by medical reimbursement specialists and peer review.

-   Although we have considered the major surrogate variables, information on individual-based risk factors for dementia, including smoking, genetic mutation, family history, vitamin D consumption, sleep patterns, caffeine use and education level, was unavailable in this database.

Introduction {#s1}
============

Dementia, a syndrome representing a cluster of disturbances in cognitive functioning, is currently the leading chronic cause of irreversible disability among elderly patients.[@R1] According to a WHO estimate, more than 30 million people are living with dementia worldwide, and this number is expected to increase by more than three times by 2050.[@R2]

The most common causes of dementia are Alzheimer disease (AD), vascular dementia, Parkinson disease (PD) and neurodegenerative diseases; these conditions have different pathogeneses that lead to a decline in cognition.[@R4] Because dementia is the end result of a complex process involving genetic defects,[@R5] hypoperfusion, oxidative stress,[@R6] mitochondrial dysfunction[@R7] and protein deposition,[@R8] the aetiology of dementia is multifactorial.

Typically, accumulation of fibrous amyloid-β (Aβ) plaques or protein fibrils of α-synuclein is the hallmark of AD, whereas aggregation of α-synuclein in the Lewy bodies is the hallmark of PD.[@R9] The levels of Aβ are associated with the severity of AD.[@R11] Bachhuber *et al*[@R12] reported that α-synuclein is also associated with the inhibition of Aβ plaque formation; these findings suggest an overlap between the pathogeneses of AD and PD.

In murine models, intragastric injection of rotenone-initiated α-synuclein can reproduce the progression of PD pathology[@R13] and vagotomy can stop the spread of PD pathology.[@R14] Vagotomy is the surgical resection of the vagus nerve, and it is performed to reduce acid secretion for managing complicated peptic ulcer disease (PUD).[@R15] Two surgical strategies of vagotomy are available: truncal vagotomy, in which the trunk of the vagus nerve is cut to innervate the abdomen, and selective vagotomy, in which the vagus nerve is resected to innervate the fundus and body of the stomach.[@R16] Liu *et al*[@R17] used a Swedish database to investigate the association between vagotomy and the risk of PD, and found that vagotomy was not associated with the risk of PD overall. However, a study by Svensson *et al*,[@R18] which was conducted using a database from Denmark, revealed an association between complete truncal vagotomy and a decreased risk for subsequent PD. Thus, the association between vagotomy and PD remains inconclusive. The aforementioned observations also suggest that vagotomy may reduce the risk of other neurodegenerative diseases, such as AD. However, clinical evidence in the form of data supporting this hypothesis is not available. Because dementia is the most common clinical sign and the result of most neurodegenerative diseases, we used the National Health Insurance (NHI) registration database to determine the association between vagotomy and dementia risk.

Methods {#s2}
=======

Data source {#s2a}
-----------

The Taiwan NHI programme, launched in March 1995, currently covers more than 99% of the 23.72 million people in Taiwan.[@R19] The inpatient database was used for this nationwide population-based retrospective cohort study. The details of the programme and inpatient databases have been discussed in previous studies.[@R20]

Diseases were coded according to the 2001 International Classification of Disease, Revision 9, Clinical Modification (ICD-9-CM). The Institutional Review Board also specifically waived the consent requirement.

Sampled participants {#s2b}
--------------------

Patients aged more than 20 years old who had undergone vagotomy (ICD-9-OP codes 44.0) formed the vagotomy cohort. The dates of the first hospitalisation for vagotomy were defined as the index dates of the vagotomy patients. Patients with a history of dementia (ICD-9-CM codes 290, 294.1 and 331.0) before the index date were excluded.

Patients who had undergone vagotomy were matched (1:1 ratio) with those who did not undergo vagotomy according to their propensity score through nearest neighbour matching, initially to the eighth digit and then as required to the first digit.[@R22] Therefore, matches were first made within a calliper width of 0.0000001, and then the calliper width was increased for unmatched cases to 0.1. We considered the matching criteria and performed a rematch (greedy algorithm) without replacement. For each vagotomy patient, the corresponding comparisons were selected based on the nearest propensity score. The date of enrolment in non-vagotomy cohort was matched with the same year and month of the vagotomy cohort, by the random assignment method. The propensity scores were calculated using logistic regression to estimate the probability of the surgery status using baseline variables of sex, age, and comorbidities such as diabetes, hypertension, hyperlipidaemia, stroke, coronary artery disease, chronic kidney disease, liver disease, osteoarthritis, chronic obstructive pulmonary disease, depression, head injury, PD, cancer or PUD. The samples were matched with sex, age, comorbidities and index year to reduce confounding effects of sex, age and comorbidities, and to have a valid measure of follow-up person-years. All of the study participants were followed up from the index date to the occurrence of dementia, withdrawal from the NHI programme or the end of 2011, whichever occurred first. Most important of all, there would be no any event of vagotomy in the control cohort during the follow-up period.

Statistical analysis {#s2c}
--------------------

The frequency and percentage for categorical variables, as well as the mean and SD for continuous variables, were calculated for the vagotomy and non-vagotomy cohorts. The differences in distribution between the two cohorts were assessed using standardised mean differences. A standardised mean difference of ≤0.1 indicated a negligible difference between the two cohorts.[@R23] The follow-up time in person-years estimated the incidence density of dementia among different risk factors and incidence density stratified by age, sex, comorbidity and follow-up period. Cox proportional hazards models stratifying on the matched pairs were performed to estimate the HR and 95% CI of developing dementia associated with vagotomy cohort, compared with non-vagotomy cohort. When the patients were stratified according to sex, age, comorbidity and follow-up period (using the first quartile and second quartile as a cut-off), the relative risk of dementia in the vagotomy and non-vagotomy cohorts was also compared using Cox regression models. To address the concern of constant proportionality, we examined the proportional hazard model assumption using a test of scaled Schoenfeld residuals. All analyses were performed using SAS V.9.4 and statistical significance was set at P\<0.05.[@R24]

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} lists the characteristics of the study cohort. We identified 155 944 patients with vagotomy; hence, 155 944 patients were recruited for the non-vagotomy cohort. Men accounted for approximately 79% of the patients in each cohort and most of the patients were aged ≥50 years (61.7% vs 61.7%). Specifically, the mean age of the patients was 56.6±17.4 years for the vagotomy cohort and 56.7±17.3 years for the non-vagotomy cohort. The major comorbidities in both cohorts were PUD (96.2% vs 96.2%), hypertension (21.1% vs 21.1%) and diabetes (15.2% vs 15.1%). The mean follow-up periods were 5.88±3.80 and 6.58±3.35 years for the vagotomy and non-vagotomy cohorts, respectively. The incidence of dementia was 2.43 and 2.84 per 1000 person-years in the vagotomy and non-vagotomy cohorts, respectively. Results showed that there was no significant relationship between Schoenfeld residuals for vagotomy and follow-up time (P=0.07) in the model evaluating the dementia risk. The vagotomy cohort was not associated with dementia compared with the non-vagotomy cohort (HR=1.09, 95% CI 0.87 to 1.36). The risk of dementia in the patients who were ≥65 years old was 74.4-fold higher than in those who were ≤49 years old (95% CI 36.8 to 150.5). Furthermore, the multivariable models showed that dementia was independently associated with comorbidities, particularly stroke (HR=1.84, 95% CI 1.47 to 2.29), head injury (HR=1.66, 95% CI 1.23 to 2.24) and PD (HR=2.00, 95% CI 1.19 to 3.38) ([table 2](#T2){ref-type="table"}).

###### 

Demographic characteristics and comorbidities in the vagotomy and non-vagotomy cohorts

                                           Vagotomy        Standard mean difference\*   
  ---------------------------------------- --------------- ---------------------------- -------
  Sex                                                                                   
   Women                                   3409 (21.4)     3397 (21.3)                  0.002
   Men                                     12 535 (78.6)   12 547 (78.7)                0.002
  Age-stratified                                                                        
   ≤49                                     6115 (38.4)     6114 (38.4)                  0.000
   50--64                                  3938 (24.7)     3939 (24.7)                  0.000
   65+                                     5891 (37.0)     5891 (37.0)                  0.000
   Age, mean±SD                            56.7±17.3       56.6±17.4                    0.01
  Comorbidity                                                                           
   Diabetes                                2399 (15.1)     2421 (15.2)                  0.004
   Hypertension                            3359 (21.1)     3360 (21.1)                  0.000
   Hyperlipidaemia                         584 (3.66)      613 (3.84)                   0.01
   Stroke                                  1334 (8.37)     1340 (8.40)                  0.001
   Coronary artery disease                 1379 (8.65)     1381 (8.66)                  0.000
   Chronic kidney disease                  613 (3.84)      632 (3.96)                   0.01
   Liver disease                           1834 (11.5)     1846 (11.6)                  0.002
   Osteoarthritis                          498 (3.12)      521 (3.27)                   0.01
   Chronic obstructive pulmonary disease   158 (0.99)      153 (0.96)                   0.003
   Depression                              191 (1.20)      190 (1.19)                   0.001
   Head injury                             976 (6.12)      994 (6.23)                   0.01
   Parkinson's disease                     117 (0.73)      108 (0.68)                   0.01
   Cancer                                  597 (3.74)      619 (3.88)                   0.01
   Peptic ulcer disease                    15 343 (96.2)   15 343 (96.2)                0.000

\*A standardised mean difference of ≤0.10 indicates a negligible difference between the two cohorts.

###### 

Incidences of and risk factors for dementia

  Variable                                Event   Person-years   Rate†   HR (95% CI)
  --------------------------------------- ------- -------------- ------- -----------------------
  Vagotomy                                                               
   No                                     298     104 932        2.84    1.00
   Yes                                    228     93 707         2.43    1.09 (0.87 to 1.36)
  Age group, year                                                        
   ≤49                                    8       91 483         0.09    1.00
   50--64                                 51      51 513         0.99    
   65+                                    467     55 643         8.39    
  Sex                                                                    
   Female                                 143     39 468         3.62    1.00 (0.06 to 16.0)
   Male                                   383     159 171        2.41    1.00
  Comorbidity                                                            
  Diabetes                                                               
   No                                     405     177 247        2.28    1.00
   Yes                                    121     21 391         5.66    1.01 (0.82 to 1.25)
  Hypertension                                                           
   No                                     289     169 471        1.71    1.00
   Yes                                    237     29 168         8.13    
  Hyperlipidaemia                                                        
   No                                     497     193 049        2.57    1.00
   Yes                                    29      5590           5.19    3.00 (0.31 to 28.8)
  Stroke                                                                 
   No                                     400     188 269        2.12    1.00
   Yes                                    126     10 370         12.2    
  Coronary artery disease                                                
   No                                     416     187 358        2.22    1.00
   Yes                                    110     11 281         9.75    2.00 (0.18 to 22.1)
  Chronic kidney disease                                                 
   No                                     494     194 635        2.54    1.00
   Yes                                    32      4004           7.99    1.33 (0.93 to 1.92)
  Liver disease                                                          
   No                                     442     180 865        2.44    1.00
   Yes                                    84      17 774         4.73    1.20 (0.95 to 1.52)
  Osteoarthritis                                                         
   No                                     502     194 322        2.58    1.00
   Yes                                    24      4317           5.56    0.76 (0.50 to 1.15)
  Chronic obstructive pulmonary disease                                  
   No                                     513     197 076        2.60    1.00
   Yes                                    13      1562           8.32    1.67 (0.96 to 2.90)
  Depression                                                             
   No                                     420     196 769        2.64    1.00
   Yes                                    6       1869           3.21    1.03 (0.46 to 2.32)
  Head injury                                                            
   No                                     478     188 290        2.54    1.00
   Yes                                    48      10 349         4.64    
  Parkinson's disease                                                    
   No                                     511     197 771        2.58    1.00
   Yes                                    15      868            17.3    
  Cancer                                                                 
   No                                     516     194 585        2.65    1.00
   Yes                                    10      4054           2.47    0.52 (0.05 to 5.51)
  Peptic ulcer disease                                                   
   No                                     10      6542           1.53    1.00
   Yes                                    516     192 096        2.69    2.11 (1.13 to 3.95)\*

\*P\<0.05

†Incidence rate per 1000 person-years.

[Table 3](#T3){ref-type="table"} compares the risk of dementia between the vagotomy and non-vagotomy cohorts and also presents the risk stratified by sex, age, comorbidity and follow-up period. Female vagotomy patients had a 1.56-fold higher risk of dementia than female patients from the non-vagotomy cohort did (HR=1.56, 95% CI 1.00 to 2.44). When compared with the non-vagotomy patients, the vagotomy patients had higher risk of dementia in those aged ≤64 years (HR=2.07, 95% CI 1.12 to 3.83).

###### 

Incidence densities of dementia HRs between the vagotomy and non-vagotomy cohorts based on demographic characteristics and comorbidities

                     Vagotomy   HR (95% CI)                                
  ------------------ ---------- ------------- ------ ----- -------- ------ -----------------------
  Sex                                                                      
   Women             77         21 364        3.60   66    18 104   3.65   1.56 (1.00 to 2.44)\*
   Men               221        83 568        2.64   162   75 603   2.14   0.96 (0.74 to 1.24)
  Stratify age                                                             
   ≤64               24         73 656        0.33   35    69 339   0.50   2.07 (1.12 to 3.83)\*
   ≥65               274        31 275        8.76   193   24 367   7.92   0.97 (0.76 to 1.24)
  Comorbidity‡                                                             
   No                1          2156          0.46   1     1493     0.67   --
   Yes               297        102 776       2.89   227   92 214   2.46   1.08 (0.86 to 1.35)
  Follow-up period                                                         
   \<4               131        43 502        3.01   116   38 634   3.00   1.24 (0.94 to 1.63)
   4--7              119        34 038        3.50   87    30 274   2.87   0.91 (0.59 to 1.40)
   ≥7                48         19 534        2.46   25    17 780   1.41   0.50 (0.17 to 1.46)

\*P\<0.05.

†Incidence rate per 1000 person-years.

‡Comorbidity: patients with any one of the listed comorbidities were classified as the comorbidity group.

PY, person-years.

We further assessed the association between vagotomy and dementia risk stratified by sex and age ([table 4](#T4){ref-type="table"}). Among the men, the effects of vagotomy on dementia risk were not associated with age (HR=1.77, 95% CI 0.90 to 3.49 for subgroup aged ≤64 years; HR=0.85, 95% CI 0.64 to 1.14 for subgroup aged ≥65 years).

###### 

Incidence and HRs of dementia, stratified by age and sex, between the vagotomy and non-vagotomy cohorts

  Variables   Men   HR (95% CI)   Women   HR (95% CI)                                                 
  ----------- ----- ------------- ------- ------------- --------------------- ---- ------ ---- ------ ---------------------
  Age                                                                                                 
  ≤64         19    0.31          27      0.46          1.77 (0.90 to 3.49)   5    0.42   8    0.73   4.00 (0.85 to 18.8)
  ≥65         202   9.23          135     7.87          0.85 (0.64 to 1.14)   72   7.68   58   8.05   1.40 (0.88 to 2.24)

\*Incidence rate per 1000 person-years.

Furthermore, the truncal vagotomy patients exhibited no association with risk of dementia, compared with the non-vagotomy patients (HR=1.05, 95% CI 0.87 to 1.25) ([table 5](#T5){ref-type="table"}). Similarly, compared with non-vagotomy cohort, the types of vagotomy, including trunk, highly selective and other selective vagotomy were not associated with risk of dementia ([table 5](#T5){ref-type="table"}). [Figure 1](#F1){ref-type="fig"} shows the cumulative incidence for vagotomy group compared with non-vagotomy cohort (log-rank test P=0.08).

![Cumulative incidence of dementia in the vagotomy and non-vagotomy cohorts.](bmjopen-2017-019582f01){#F1}

###### 

Incidence and HRs of dementia among the vagotomy and non-vagotomy cohorts

  Variable                    n        Event   Person-years   Rate\*   HR (95% CI)
  --------------------------- -------- ------- -------------- -------- ----------------------
  Control                     15 944   298     104 932        2.84     1 (reference)
  Vagotomy                                                             
   Truncal vagotomy           12 999   192     77 219         2.49     1.04 (0.87 to 1.25)
   Highly selective           1035     8       6141           1.30     0.84 (0.42 to 1. 69)
   Other selective vagotomy   101      1       529            1.89     0.80 (0.11 to 5.73)

\*Rate, incidence rate per 1000 person-years.

To address the concern of constant proportionality, we examined the proportional hazard model assumption using a test of scaled Schoenfeld residuals. Results showed that there was no significant relationship between Schoenfeld residuals for vagotomy and follow-up time (P=0.07) in the model evaluating the dementia risk.

Discussion {#s4}
==========

Recent studies have reported that the vagus nerve is associated with the transport of α-synuclein and progression of PD.[@R14] A nationwide population-based study by Svensson *et al* revealed that truncal vagotomy is associated with a decreased risk of subsequent PD.[@R18] However, Liu *et al*[@R17] reported that neither truncal nor selective vagotomy is associated with a protective effect against PD. Similar to the findings of Liu *et al*,[@R17] our study revealed that vagotomy is not associated with overall risk of dementia. However, vagotomy, in those women or patients aged ≤64 years old, is associated with higher risk of dementia.

Several explanations for these results are possible. First, dementia has several aetiologies, including PD, AD, vascular dementia and other neurodegenerative diseases. Braak *et al*[@R26] proposed that the pathogenic process of PD originates when an environmental insult enters the body and is transmitted to the brain. Furthermore, the pathogenic process is mediated by the neurontransport of α-synuclein. Sevenson *et al* reported that truncal vagotomy is associated with a decreased risk of PD,[@R16] which thus supported the hypothesis of Braak *et al*.[@R26] A major component of Lewy bodies in PD, α-synuclein, was first isolated from plaques in the brains of patients with AD.[@R27] Although α-synuclein is associated with the development of PD and AD, the enteric route might be a spread source for neurodegenerative diseases.[@R28] Thus, vagotomy might not be associated directly with the risk of dementia.

Another possible explanation is the microbiome effect of vagotomy. In animal models of sepsis, the vagal nerve has been proposed to be involved in the regulation of inflammatory responses.[@R29] Li *et al*[@R30] described a case of impaired intestinal microbiota barrier following vagotomy and subsequent rescue after microbiota transplantation. Recently, it has been recognised that the human microbiome of the gastrointestinal tract may affect the brain and behaviour, an association that has been named the gut--brain axis.[@R31] The brains of patients with Parkinson-dementia and AD were found to have elevated levels of beta-N-methylamino-L-alanine.[@R32] Schwartz *et al*[@R33] proposed that the host bacteria amyloids contribute to misfolding and amyloidogenic diseases such as AD. Thus, vagotomy might alter the microbiome of the gastrointestinal tract. However, the negative effects of an altered microbiome following vagotomy may attenuate the possible positive effects discussed by Braak *et al*. The effect of vagotomy on neurological dysfunction therefore remains only vaguely defined. One interesting finding of this study is that vagotomy, in those women or patients aged ≤64 years-old, is associated with higher risk of dementia. Further studies are needed to clarify whether and why vagotomy are associated with the risk of dementia in a group of women or aged ≤64 years old.

This study has several limitations. First, we defined dementia as an outcome instead of a specific neurodegenerative disease. Dementia is the most common presentation of neurodegenerative diseases, including AD and PD. The diagnosis of AD is stricter than that of dementia and requires distinct clinical and laboratory features.[@R34] Thus, in this study, we used dementia as an outcome and adjusted cardiovascular-related comorbidities for vascular dementia to avoid the possible bias of underdiagnosis related to AD and other neurodegenerative diseases. The discrimination and validity for subtypes of dementia are difficult in this study based on coding. We did not analyse the association between vagotomy and subtypes of dementia. Second, although we have considered the major surrogate variables, information on individual-based risk factors for dementia, including smoking, genetic mutation, family history, vitamin D consumption, sleep patterns, caffeine use and education level, was unavailable in this database. Further, the vagotomy cohort might have more medical visits and more chances to be diagnosed with dementia, and possible surveillance and detection bias should be mentioned here. The follow-up period of this study is relatively short. Since our data showed that vagotomy had no association with dementia before 7 years, but may provide protection for dementia after 7 years, it would be possible that vagotomy might be protective for dementia once the follow-up duration is longer. Further, the number of dementia events is small in this study; thus, the conclusion and presumption would not be precise and valid. Longitudinal cohort studies of longer follow-up duration are necessary to clarify the possible protective role of vagotomy for dementia. Finally, most of the study population is Taiwanese; thus, it needs caution to translate and generalise our findings to other population. The generalisability of our results might be limited.

In conclusion, the current nationwide cohort study revealed that vagotomy, either truncal or selective, was not associated with risk of dementia. Although one study showed that truncal vagotomy reduces the risk of PD,[@R17] our study offers preliminary evidence that the association between vagotomy and dementia is not direct.
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